REGISTER
Akeso’s IL-17A mAb Gumokimab Approved in China for Psoriasis
On June 11, China’s NMPA approved Akeso Biopharma’s IL-17A monoclonal antibody gumokimab for moderate-to-severe plaque psoriasis. In the pivotal Phase III AK111-301 trial, gumokimab showed rapid onset, with clinical improvement seen by Week 2. At Week 12, PASI 75 reached nearly 96%, while PASI 100 exceeded 40%. By Week 52, PASI 75 was nearly 100% and PASI 100 reached 65%. Safety was comparable to placebo.

On June 11, the website of China’s National Medical Products Administration (NMPA) showed that Akeso Biopharma’s gumokimab had been approved for marketing for the treatment of moderate-to-severe plaque psoriasis.

Gumokimab is a novel humanized IgG1 monoclonal antibody independently developed by Akeso that targets interleukin-17A (IL-17A). It specifically binds to the pro-inflammatory cytokine IL-17A, blocks IL-17A receptor-mediated signaling pathways on immune-related cells, and inhibits the onset and progression of related immune-inflammatory responses.

Akeso has conducted a total of four clinical studies of gumokimab in patients with moderate-to-severe plaque psoriasis, including one pivotal Phase III clinical study (AK111-301) and three supportive studies.

Efficacy results showed that gumokimab has a rapid onset of action in the treatment of moderate-to-severe plaque psoriasis, with strong long-term efficacy maintenance and continued improvement in treatment outcomes, providing an effective treatment option for patients seeking better therapeutic results.

  • Gumokimab showed a rapid onset of action, with clinically meaningful improvement observed after just 2 weeks of treatment.

  • Gumokimab demonstrated strong short-term efficacy. At Week 12, the PASI 75 response rate was nearly 96%, the sPGA 0/1 response rate was nearly 90%, the PASI 90 response rate was nearly 80%, and the PASI 100 response rate exceeded 40%. All efficacy endpoints were significantly superior to those in the control group.

  • Gumokimab also demonstrated strong long-term efficacy, with sustained improvement and durable maintenance over time. At Week 52, the PASI 75 response rate was nearly 100%, while the sPGA 0/1 response rate remained stable. The PASI 90 and PASI 100 response rates further improved to nearly 90% and 65%, respectively.

  • Safety data showed that, after exposure adjustment during both the placebo-controlled phase and the overall treatment phase, the incidence of adverse events was comparable between the gumokimab and placebo groups, with numerically slightly lower rates in the gumokimab group.

Psoriasis is an immune-mediated chronic recurrent disease driven by both genetic and environmental factors. Plaque psoriasis is the most common type, accounting for about 80% of cases. Skin lesions and associated symptoms not only significantly reduce quality of life, but also place a substantial burden on patients through their impact on work, social life, mental health, and treatment-related costs. There is an urgent need for patients with psoriasis to initiate biologic therapy as early as possible, intervene early in disease progression, and achieve better treatment outcomes.

Currently, eight IL-17A-targeted therapies have been approved worldwide. The other seven are secukinumab (Novartis), ixekizumab (Eli Lilly), bimekizumab (UCB), vunakizumab (Hengrui Medicine), serikizumab (Zhixiang Jintai), netakimab (Biocad), and anmukitamab (3SBio). Except for netakimab, all have been launched in China.

0
0
Loading